miRConnect 2.0: identification of oncogenic, antagonistic miRNA families in three human cancers

Area of Science:

• Oncology
• Genomics
• Bioinformatics

Background:

• MicroRNAs (miRNAs) are classified as tumor suppressors or oncogenes based on their function.
• The role of oncogenic miRNAs in promoting distinct steps of tumor progression raises questions about potential functional antagonism.
• A novel method, miRConnect, was developed to link miRNAs to biological functions without relying on target predictions.

Purpose of the Study:

• To extend the miRConnect analysis to primary human cancers using The Cancer Genome Atlas (TCGA) data.
• To identify functionally antagonistic groups of miRNAs by correlating miRNA expression with oncogenic signatures.
• To investigate the clinical relevance of miRNA functional antagonism in patient survival.

Main Methods:

• Utilized miRConnect 2.0 to analyze miRNA and messenger RNA (mRNA) expression data from ovarian cancer, glioblastoma, and kidney renal clear cell carcinoma.
• Correlated clustered miRNA expression with 158 oncogenic gene signatures.
• Analyzed patient data to assess the relationship between miRNA expression ratios and overall survival.

Main Results:

• Identified functionally antagonistic miRNA groups, including the miR-17 family (agonists) and miR-221/222 (antagonists).
• Both miR-17 ~ 92 and miR-221/222 are considered oncogenic, demonstrating functional antagonism between different oncogenic miRNAs.
• Patient data showed predominance of either agonistic or antagonistic miRNAs; in glioblastoma, a high miR-17 to miR-221/222 ratio predicted better survival.

Conclusions:

• miRConnect 2.0 effectively identifies miRNA activities relevant to primary cancers.
• New correlation data linking deregulated miRNAs and mRNAs in three primary cancers are publicly available.
• Functional antagonism between oncogenic miRNAs like miR-17 and miR-221/222 has significant implications for cancer progression and patient outcomes.